Entity identity
Confirm the exact peptide, analog, fragment, formulation, and aliases before transferring any evidence.
Methodology / Traffic-first v1
One model. No evidence blur.
The visible bars describe evidence depth, not whether a peptide “works.” The decision comes from the study design, population, product status, limitations, and sources beneath them.
0—5
Human evidence
Show the maturity of relevant human research without turning evidence depth into a benefit score.
Preclinical evidence
Keep cell and animal signals visible, but never present them as proof in people.
Indication & population
Tie every finding and approval to the population and question that were actually studied.
Status
Separate FDA product approval, compounding context, and WADA classification.
Sources & uncertainty
Attach inspectable primary or official sources and state the most important unresolved gap.
EVIDENCE DEPTH
0Not reviewed1Very limited2Early3Developing4Substantial5Mature
The non-negotiable rule
Mechanism is not outcome evidence. Animal research is not human proof. Approval for one product and population is not approval for every version or use.